Jeffrey J Olson

List of Publications by Year
in descending order

121 papers	4,891 citations	101496 36 h-index	102432 66 g-index
132 all docs	132 docs citations	132 times ranked	7062 citing authors

#	Article	IF	Citations
1	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2022, 158, 265-321.	1.4	5
2	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of radiation therapy in the management of progressive and recurrent glioblastoma in adults. Journal of Neuro-Oncology, 2022, 158, 255-264.	1.4	16
3	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Journal of Clinical Oncology, 2022, 40, 403-426.	0.8	67
4	Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of cytotoxic chemotherapy and other cytotoxic therapies in the management of progressive glioblastoma in adults. Journal of Neuro-Oncology, 2022, 158, 225-253.	1.4	7
5	Predictors of Permanent Cerebrospinal Fluid Diversion after Craniotomy for Vestibular Schwannoma. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.4	0
6	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults. Journal of Neuro-Oncology, 2022, 158, 167-177.	1.4	4
7	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 2022, 24, 358-383.	0.6	1
8	Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. Journal of Neuro-Oncology, 2022, 157, 187-195.	1.4	6
9	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Progressive Glioblastoma in Adults: Update of the 2014 Guidelines. Neurosurgery, 2022, 90, e112-e115.	0.6	1
10	Distinct phenotypic states and spatial distribution of CD8+ TÂcell clonotypes in human brain metastases. Cell Reports Medicine, 2022, 3, 100620.	3.3	29
11	Dexamethasone and brain metastasis-infiltrating CD8+ T cells.. Journal of Clinical Oncology, 2022, 40, e15075-e15075.	0.8	0
12	Impact of systemic therapy regimen on survival of PCNSL.. Journal of Clinical Oncology, 2022, 40, 2070-2070.	0.8	0
13	YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. Clinical Cancer Research, 2021, 27, 1553-1569.	3.2	65
14	Adjuvant Radiotherapy Versus Watchful Waiting for World Health Organization Grade II Atypical Meningioma: A Single-Institution Experience. Neurosurgery, 2021, 88, E435-E442.	0.6	18
15	Guidelines in the management of CNS tumors. Journal of Neuro-Oncology, 2021, 151, 345-359.	1.4	10
16	Co-Occurrence Conundrum: Brain Metastases from Lung Adenocarcinoma, Radiation Necrosis, and Gliosarcoma. Case Reports in Oncology, 2021, 14, 487-492.	0.3	2
17	N-cadherin upregulation mediates adaptive radioresistance in glioblastoma. Journal of Clinical Investigation, 2021, 131, .	3.9	43
18	Synthesis, Radiolabeling, and Biological Evaluation of the trans-Stereoisomers of 1-Amino-3-(fluoro-¹⁸F)-4-fluorocyclopentane-1-carboxylic Acid as PET Imaging Agents. ACS Pharmacology and Translational Science, 2021, 4, 1195-1203.	2.5	3

#	Article	IF	Citations
19	Gene expression signature to predict radiation response in lower-grade gliomas.. Journal of Clinical Oncology, 2021, 39, 2019-2019.	0.8	1
20	3D whole-brain metabolite imaging to improve characterization of low-to-intermediate grade gliomas. Journal of Neuro-Oncology, 2021, 153, 303-311.	1.4	6
21	Permanent Cerebrospinal Fluid Diversion in Adults With Posterior Fossa Tumors: Incidence and Predictors. Neurosurgery, 2021, 89, 987-996.	0.6	11
22	Congress of neurological surgeons systematic review and evidence-based guidelines for the treatment of adults with progressive glioblastoma update: introduction and methods. Journal of Neuro-Oncology, 2021, , 1.	1.4	2
23	Surgical Outcomes of Novel Collagen Tile Cesium Brachytherapy for Recurrent Intracranial Tumors at a Tertiary Referral Center. Cureus, 2021, 13, e19777.	0.2	4
24	CBMS-7 IGF1/N-cadherin/Clusterin signaling axis mediates adaptive radioresistance of glioma stem cells. Neuro-Oncology Advances, 2021, 3, vi3-vi3.	0.4	0
25	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. International Journal of Cancer, 2020, 146, 739-748.	2.3	23
26	EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway. Oncogene, 2020, 39, 1041-1048.	2.6	33
27	Sheltered Neurosurgery During COVID-19: The Emory Experience. World Neurosurgery, 2020, 144, e204-e209.	0.7	30
28	High-Grade Sarcoma Arising within a Previously Irradiated Vestibular Schwannoma: A Case Report and Literature Review. World Neurosurgery, 2020, 144, 99-105.	0.7	5
29	The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update. Journal of Neuro-Oncology, 2020, 150, 95-120.	1.4	18
30	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of chemotherapeutic management and antiangiogenic treatment of newly diagnosed glioblastoma in adults. Journal of Neuro-Oncology, 2020, 150, 165-213.	1.4	6
31	Cytoreductive surgery in the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update. Journal of Neuro-Oncology, 2020, 150, 121-142.	1.4	12
32	The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update. Journal of Neuro-Oncology, 2020, 150, 215-267.	1.4	19
33	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2020, 150, 269-359.	1.4	8
34	Congress of neurological surgeons systematic review and evidence-based clinical practice parameter guidelines for the treatment of adults with newly diagnosed glioblastoma: Introduction and Methods. Journal of Neuro-Oncology, 2020, 150, 87-93.	1.4	4
35	Metastases to the Central Nervous System: A Comprehensive Guide on Current Management and Future Directions. Neurosurgery Clinics of North America, 2020, 31, xiii-xiv.	0.8	0
36	Synthesis, Radiolabeling, and Biological Evaluation of the cis Stereoisomers of 1-Amino-3-Fluoro-4-(fluoro-¹⁸F)Cyclopentane-1-Carboxylic Acid as PET Imaging Agents. Journal of Medicinal Chemistry, 2020, 63, 12008-12022.	2.9	9

#	Article	IF	Citations
37	Invasive sphenoid sinus aspergillosis mimicking sellar tumor: a report of 4 cases and systematic literature review. Chinese Neurosurgical Journal, 2020, 6, 10.	0.3	8
38	Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2020, 108, 157-163.	0.4	25
39	EXTH-27. YAP/TAZ TRANSCRIPTIONAL CO-ACTIVATORS CREATE THERAPEUTIC VULNERABILITY TO VERTEPORFIN IN EGFR MUTANT GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii92-ii92.	0.6	1
40	[18F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis. EJNMMI Research, 2020, 10, 148.	1.1	14
41	CTNI-13. UPDATES ON CLINICAL OUTCOMES AND TUMOR RECURRENCE PATTERNS OF A HUMAN PILOT STUDY ASSESSING EFFICACY OF BELINOSTAT (PXD-101) COMBINING WITH CHEMORADIATION IN TREATING GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii44-ii44.	0.6	0
42	STEM-16. IGF1/N-CADHERIN/b-CATENIN/CLUSTERIN SIGNALING AXIS MEDIATES ADAPTIVE RADIORESISTANCE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii199-ii199.	0.6	0
43	Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression. Neuro-Oncology, 2019, 21, 234-241.	0.6	16
44	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Treatment of Adults With Metastatic Brain Tumors: Executive Summary. Neurosurgery, 2019, 84, 550-552.	0.6	37
45	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors. Neurosurgery, 2019, 84, E152-E155.	0.6	87
46	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Prophylactic Anticonvulsants in the Treatment of Adults with Metastatic Brain Tumors. Neurosurgery, 2019, 84, E195-E197.	0.6	48
47	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Emerging and Investigational Therapies for the Treatment of Adults With Metastatic Brain Tumors. Neurosurgery, 2019, 84, E201-E203.	0.6	39
48	Gliosarcoma: distinct molecular pathways and genomic alterations identified by DNA copy number/SNP microarray analysis. Journal of Neuro-Oncology, 2019, 143, 381-392.	1.4	25
49	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Treatment Options for Adults With Multiple Metastatic Brain Tumors. Neurosurgery, 2019, 84, E180-E182.	0.6	47
50	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults With Metastatic Brain Tumors. Neurosurgery, 2019, 84, E168-E170.	0.6	81
51	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Steroids in the Treatment of Adults With Metastatic Brain Tumors. Neurosurgery, 2019, 84, E189-E191.	0.6	52
52	Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI. Tomography, 2019, 5, 53-60.	0.8	23
53	82Rubidium chloride PET discrimination of recurrent intracranial malignancy from radiation necrosis. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, , .	0.4	0
54	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Otologic and Audiologic Screening for Patients With Vestibular Schwannomas. Neurosurgery, 2018, 82, E29-E31.	0.6	40

#	Article	IF	Citations
55	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Hearing Preservation Outcomes in Patients With Sporadic Vestibular Schwannomas. Neurosurgery, 2018, 82, E35-E39.	0.6	91
56	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Surgical Resection for the Treatment of Patients With Vestibular Schwannomas. Neurosurgery, 2018, 82, E40-E43.	0.6	56
57	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Intraoperative Cranial Nerve Monitoring in Vestibular Schwannoma Surgery. Neurosurgery, 2018, 82, E44-E46.	0.6	45
58	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Pathological Methods and Prognostic Factors in Vestibular Schwannomas. Neurosurgery, 2018, 82, E47-E48.	0.6	5
59	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Emerging Therapies for the Treatment of Patients With Vestibular Schwannomas. Neurosurgery, 2018, 82, E52-E54.	0.6	42
60	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Imaging in the Diagnosis and Management of Patients With Vestibular Schwannomas. Neurosurgery, 2018, 82, E32-E34.	0.6	45
61	Handedness and the risk of glioma. Journal of Neuro-Oncology, 2018, 137, 639-644.	1.4	4
62	Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlladeL WAfer ImplaNT registry. CNS Oncology, 2018, 7, CNS08.	1.2	12
63	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Radiosurgery and Radiation Therapy in the Management of Patients With Vestibular Schwannomas. Neurosurgery, 2018, 82, E49-E51.	0.6	55
64	Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Treatment of Adults With Vestibular Schwannomas: Executive Summary. Neurosurgery, 2018, 82, 129-134.	0.6	32
65	Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. Journal of Neuro-Oncology, 2018, 136, 327-333.	1.4	15
66	[18F]Fluciclovine PET discrimination between high- and low-grade gliomas. EJNMMI Research, 2018, 8, 67.	1.1	42
67	BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell, 2018, 33, 1004-1016.e5.	7.7	52
68	Older age at the completion of linear growth is associated with an increased risk of adult glioma. Cancer Causes and Control, 2017, 28, 709-716.	0.8	4
69	Update on the evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: the role of initial chemotherapy. Journal of Neuro-Oncology, 2016, 128, 487-489.	1.4	4
70	Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2016, 130, 193-201.	1.4	21
71	PDTB-28. TARGETING MEDULLOBLASTOMA WITH BENZODIAZAPINES DELIVERED USING TUNABLE BIODEGRADABLE HYDROGELS. Neuro-Oncology, 2016, 18, vi156-vi156.	0.6	0
72	Semi-Automated Volumetric and Morphological Assessment of Glioblastoma Resection with Fluorescence-Guided Surgery. Molecular Imaging and Biology, 2016, 18, 454-462.	1.3	28

#	Article	IF	Citations
73	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	13.7	266
74	Whole-brain spectroscopic MRI biomarkers identify infiltrating margins in glioblastoma patients. Neuro-Oncology, 2016, 18, 1180-1189.	0.6	94
75	Analgesic use and the risk of primary adult brain tumor. European Journal of Epidemiology, 2016, 31, 917-925.	2.5	9
76	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	5.1	274
77	A Systematic Pipeline for the Objective Comparison of Whole-Brain Spectroscopic MRI with Histology in Biopsy Specimens from Grade 3 Glioma. Tomography, 2016, 2, 106-116.	0.8	14
78	SURG-11THE IMPACT OF PRE-OPERATIVE TUMOR FEATURES ON RESECTION AND SURVIVAL OUTCOMES IN GLIOBLASTOMA: A PHASE II FLUORESCENCE-GUIDED SURGERY STUDY. Neuro-Oncology, 2015, 17, v216.3-v216.	0.6	0
79	Evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: introduction and methods. Journal of Neuro-Oncology, 2015, 125, 449-456.	1.4	16
80	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1386-1392.	0.6	50
81	Complementary therapy and survival in glioblastoma. Neuro-Oncology Practice, 2015, 2, 122-126.	1.0	25
82	The role of emerging therapy in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 631-635.	1.4	9
83	The role of biopsy in the management of patients with presumed diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 481-501.	1.4	30
84	The role of surgery in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 503-530.	1.4	147
85	The role of imaging in the management of adults with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 457-479.	1.4	81
86	Management of patients with recurrence of diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 609-630.	1.4	50
87	The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 585-607.	1.4	19
88	The role of radiotherapy in the management of patients with diffuse low grade glioma. Journal of Neuro-Oncology, 2015, 125, 551-583.	1.4	50
89	System a amino acid transport-targeted brain and systemic tumor PET imaging agents 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid. Nuclear Medicine and Biology, 2015, 42, 8-18.	0.3	17
90	Use of High-Resolution Volumetric MR Spectroscopic Imaging in Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor. American Journal of Roentgenology, 2014, 203, W158-W165.	1.0	13

#	Article	IF	Citations
91	Glioblastoma at progression: therapy of a challenging problem addressed candidly with evidence-based techniques. Journal of Neuro-Oncology, 2014, 118, 427-428.	1.4	2
92	SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nature Communications, 2014, 5, 4234.	5.8	94
93	Clinical practice guidelines in the AANS/CNS Section on Tumors: past, present and future directions. Journal of Neuro-Oncology, 2014, 119, 557-568.	1.4	1
94	Introduction, rationale, and methodology. Journal of Neuro-Oncology, 2014, 118, 429-434.	1.4	5
95	The role of imaging in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 435-460.	1.4	144
96	The role of neuropathology in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 461-478.	1.4	10
97	The role of radiotherapy in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 489-499.	1.4	68
98	The role of cytotoxic chemotherapy in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 501-555.	1.4	45
99	The role of targeted therapies in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 557-599.	1.4	35
100	The role of cytoreductive surgery in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 479-488.	1.4	55
101	The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. Journal of Neuro-Oncology, 2010, 96, 115-142.	1.4	48
102	Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma. Ca-A Cancer Journal for Clinicians, 2010, 60, 166-193.	157.7	1,182
103	Management of newly diagnosed glioblastoma: guidelines development, value and application. Journal of Neuro-Oncology, 2009, 93, 1-23.	1.4	42
104	Guidelines for the treatment of newly diagnosed glioblastoma: introduction. Journal of Neuro-Oncology, 2008, 89, 255-258.	1.4	34
105	Assessment of a balloon-tipped catheter modified for intracerebral convection-enhanced delivery. Journal of Neuro-Oncology, 2008, 89, 159-168.	1.4	30
106	Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. Journal of Neuro-Oncology, 2008, 89, 271-286.	1.4	55
107	Cytotoxic chemotherapeutic management of newly diagnosed glioblastoma multiforme. Journal of Neuro-Oncology, 2008, 89, 339-357.	1.4	20
108	Neuroradiological assessment of newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2008, 89, 259-269.	1.4	22

#	Article	IF	Citations
109	Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. Journal of Neuro-Oncology, 2008, 89, 313-337.	1.4	33
110	Diagnosis of malignant glioma: role of neuropathology. Journal of Neuro-Oncology, 2008, 89, 287-311.	1.4	88
111	Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 2008, 90, 293-299.	1.4	21
112	Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro-Oncology, 2008, 10, 617-623.	0.6	21
113	Intravascular thrombosis is more frequent in glioblastoma than other central nervous system malignancies. FASEB Journal, 2007, 21, A26.	0.2	0
114	Correlation of the response of recurrent malignant gliomas treated with interferon alpha with tumor interferon alpha gene content. International Journal of Oncology, 2004, 25, 419-27.	1.4	5
115	Neurosurgical advances in the treatment of brain tumors. Current Oncology Reports, 2000, 2, 434-437.	1.8	2
116	Intracranial Extraskeletal Mesenchymal Chondrosarcoma: Case Report. Neurosurgery, 2000, 46, 207-212.	0.6	49
117	Stereotactic radiosurgery of malignant and benign intracranial lesions utilizing a patient rotator. Radiation Oncology Investigations, 1997, 5, 20-30.	1.3	3
118	The Efficacy and Distribution of Suramin in the Treatment of the 9L Gliosarcoma. Neurosurgery, 1994, 34, 297-308.	0.6	14
119	Craniotomy for brain tumor. , 0, , 667-673.		0
120	Adjuvant Radiotherapy in Grade II, Atypical Meningioma of the Skull Base. Journal of Neurological Surgery, Part B: Skull Base, 0, , .	0.4	2
121	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults. Journal of Neuro-Oncology, 0, , .	1.4	1